IC51

BIOLOGICAL8 trials

Sponsors

Valneva Austria GmbH

Conditions

EncephalitisJapanese Encephalitis

Phase 3

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

CompletedNCT00595309

Valneva Austria GmbHJapanese Encephalitis

Start: 2007-12-31End: 2009-10-31Updated: 2014-05-16

Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51

CompletedNCT00594958

Valneva Austria GmbHJapanese Encephalitis

Start: 2006-09-30End: 2007-09-30Updated: 2024-03-21

Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

CompletedNCT00595270

Valneva Austria GmbHJapanese Encephalitis

Start: 2005-10-31End: 2009-04-30Updated: 2014-03-07

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

CompletedNCT00596271

Valneva Austria GmbHJapanese Encephalitis

Start: 2005-09-30End: 2008-08-31Updated: 2014-05-13

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

CompletedNCT00595790

Valneva Austria GmbHJapanese Encephalitis

Start: 2005-09-30End: 2007-11-30Updated: 2014-04-29

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

CompletedNCT00604708

Valneva Austria GmbHJapanese Encephalitis

Start: 2005-09-30End: 2006-09-30Updated: 2024-03-21

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

CompletedNCT00776230

Valneva Austria GmbHJapanese Encephalitis

Start: 2008-09-30End: 2010-06-30Updated: 2016-05-04

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

CompletedNCT01047839

Valneva Austria GmbHEncephalitis

Start: 2010-01-31End: 2013-08-31Updated: 2020-06-30